Dyslipidemia and Treatment Guidelines (AKA “Is Butter Really Better than Oleo?”)

This program will assist the Nurse Practitioner in obtaining the skill set needed to do risk assessment and assign goals, develop treatment practices, to best treat patients for dyslipidemia.

 *Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.50 Contact Hours; 1.50 are Pharmacology
Expiration Date: June 30, 2025 

$40

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-Determine a risk assessment and appropriate goals for ASCVD to the adult population
-Review and examine the treatment modalities and pathophysiology for cholesterol management
-Develop treatment plans to appropriately treat adults with dyslipidemia

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Gary Graf, MSN, ARNP-C have disclosed:

Novo Nordisk Speaker Diabetes Ozempic, Rybelsus

Eli Lilly Speaker Diabetes Mounjaro
Averitas Speaker Diabetes Qutenza
Sensionics
Bayer

MannKind Speaker, Stock
Speaker

Speaker, Stock CGM
Diabetic N
Nephropathy
Diabetes Eversense E3
Kerendia

V-go

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.